Article 4VBKQ Boeing Provides Damage Control After Inspector General's Report on Commercial Crew Program

Boeing Provides Damage Control After Inspector General's Report on Commercial Crew Program

by
Fnord666
from SoylentNews on (#4VBKQ)

takyon writes:

Boeing seems upset with NASA's inspector general

"We strongly disagree with the report's conclusions about CST-100 Starliner pricing and readiness, and we owe it to the space community and the American public to share the facts the Inspector General missed," Jim Chilton, vice president and general manager of Boeing Space and Launch, stated in a release posted on Boeing's website.

Boeing's response takes issue with several parts of NASA's report. But the company appears especially exercised about the claim that NASA overpaid Boeing for seats on the third through sixth Starliner missions, payment over and above what was originally agreed upon as part of the company's fixed price contract with the space agency.

"Through fair and open negotiations with NASA in a competitive environment, we offered single-mission pricing for post-certification missions 3-6, thus enabling additional flexibility and schedule resiliency to enhance future mission readiness," the Boeing statement reads.

[...] In its response, Boeing said its per-seat price was not $90 million, although the company declined to say what its actual price is or provide any documentation to support this claim. "For proprietary, competitive reasons Boeing does not disclose specific pricing information, but we are confident our average seat pricing to NASA is below the figure cited," the company's statement reads.

Previously: NASA Warned Of Safety Risks In Delayed Private Crew Launches
Boeing Received 'Unnecessary' Contract Boost for Astronaut Capsule, Watchdog Says

Original Submission

Read more of this story at SoylentNews.

External Content
Source RSS or Atom Feed
Feed Location https://soylentnews.org/index.rss
Feed Title SoylentNews
Feed Link https://soylentnews.org/
Feed Copyright Copyright 2014, SoylentNews
Reply 0 comments